Analyst Coverage

Arlinda Lee
Canaccord Genuity
Paul Choi
Goldman Sachs
Michael Schmidt
Guggenheim Securities LLC
Robert Burns
H.C. Wainwright & Co., LLC
Silvan Tuerkcan
JMP Securities
Matthew Biegler
Oppenheimer & Co., Inc.
Zegbeh Jallah
Roth Capital Partners, Inc.
Bradley Canino
Stifel Nicolaus and Company, Incorporated
Andrew Berens
SVB Leerink
David Nierengarten
Wedbush Securities Inc.
Nicholas Abbott
Wells Fargo Securities, LLC

Turning Point Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Turning Point Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Turning Point Therapeutics, Inc. or its management. Turning Point Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb